Literature DB >> 22420426

Clinical and molecular analysis of RASopathies in a group of Turkish patients.

P Ö Şimşek-Kiper1, Y Alanay, B Gülhan, C Lissewski, D Türkyilmaz, D Alehan, M Cetin, G E Utine, M Zenker, K Boduroğlu.   

Abstract

The 'RASopathies' are a group of disorders sharing many clinical features and a common pathophysiology. In this study, we aimed to clinically evaluate a group of Turkish patients and elucidate the underlying genetic etiology. Thirty-one patients with a clinical diagnosis of one of the RASopathy syndromes were included in the study. Of these, 26 (83.8%) had a clinical diagnosis of Noonan syndrome, whereas 5 had a clinical diagnosis of either Costello, LEOPARD or cardio-facio-cutaneous syndromes. Twenty of 31 (64.5%) patients were found to be mutation positive. Mutations in PTPN11, SOS1 and SHOC2 genes were detected in patients with Noonan syndrome (57.6%). Mutations in MEK1, PTPN11, BRAF and HRAS genes were detected in the remaining. Pulmonary stenosis was the most common (61.5%) cardiac anomaly. Among Noonan syndrome patients with a confirmed mutation, mild intellectual disability tended to be more common in patients with PTPN11 mutation than in those with SOS1 mutation. Hematologic evaluation revealed coagulation defects in three Noonan syndrome patients with a mutation. This is currently the largest clinical and molecular study in Turkish RASopathy patients. Our findings indicate that molecular epidemiology and genotype-phenotype correlations in RASopathies are relatively independent from the ethnic population background.
© 2012 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22420426     DOI: 10.1111/j.1399-0004.2012.01875.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  9 in total

Review 1.  A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.

Authors:  Nancy Ratner; Shyra J Miller
Journal:  Nat Rev Cancer       Date:  2015-04-16       Impact factor: 60.716

2.  Clinical and Molecular Findings of Tunisian Patients with RASopathies.

Authors:  Rim Louati; N Bouayed Abdelmoula; Imen Trabelsi; Dorra Abid; Christina Lissewski; Najla Kharrat; Samir Kamoun; Martin Zenker; Tarek Rebai
Journal:  Mol Syndromol       Date:  2014-05-23

3.  Noonan syndrome in diverse populations.

Authors:  Paul Kruszka; Antonio R Porras; Yonit A Addissie; Angélica Moresco; Sofia Medrano; Gary T K Mok; Gordon K C Leung; Cedrik Tekendo-Ngongang; Annette Uwineza; Meow-Keong Thong; Premala Muthukumarasamy; Engela Honey; Ekanem N Ekure; Ogochukwu J Sokunbi; Nnenna Kalu; Kelly L Jones; Julie D Kaplan; Omar A Abdul-Rahman; Lisa M Vincent; Amber Love; Khadija Belhassan; Karim Ouldim; Ihssane El Bouchikhi; Anju Shukla; Katta M Girisha; Siddaramappa J Patil; Nirmala D Sirisena; Vajira H W Dissanayake; C Sampath Paththinige; Rupesh Mishra; Eva Klein-Zighelboim; Bertha E Gallardo Jugo; Miguel Chávez Pastor; Hugo H Abarca-Barriga; Steven A Skinner; Eloise J Prijoles; Eben Badoe; Ashleigh D Gill; Vorasuk Shotelersuk; Patroula Smpokou; Monisha S Kisling; Carlos R Ferreira; Leon Mutesa; Andre Megarbane; Antonie D Kline; Amy Kimball; Emmy Okello; Peter Lwabi; Twalib Aliku; Emmanuel Tenywa; Nonglak Boonchooduang; Pranoot Tanpaiboon; Antonio Richieri-Costa; Ambroise Wonkam; Brian H Y Chung; Roger E Stevenson; Marshall Summar; Kausik Mandal; Shubha R Phadke; María G Obregon; Marius G Linguraru; Maximilian Muenke
Journal:  Am J Med Genet A       Date:  2017-07-27       Impact factor: 2.802

4.  Comprehensive Genetic Analysis of RASopathy in the Era of Next-Generation Sequencing and Definition of a Novel Likely Pathogenic >KRAS Variation.

Authors:  Selma Demir; Hümeyra Yaşar Köstek; Aslıhan Sanrı; Ruken Yıldırım; Fatma Özgüç Çömlek; Sinem Yalçıntepe; Murat Deveci; Emine İkbal Atlı; Engin Atlı; Damla Eker; Hakan Gürkan; Filiz Tütüncüler Kökenli
Journal:  Mol Syndromol       Date:  2022-01-07

5.  Mutation Spectrum and Phenotypic Features in Noonan Syndrome with PTPN11 Mutations: Definition of Two Novel Mutations.

Authors:  Tahir Atik; Ayca Aykut; Filiz Hazan; Huseyin Onay; Damla Goksen; Sukran Darcan; Ajlan Tukun; Ferda Ozkinay
Journal:  Indian J Pediatr       Date:  2016-01-28       Impact factor: 1.967

6.  Objective differential diagnosis of Noonan and Williams-Beuren syndromes in diverse populations using quantitative facial phenotyping.

Authors:  Antonio R Porras; Marshal Summar; Marius George Linguraru
Journal:  Mol Genet Genomic Med       Date:  2021-03-27       Impact factor: 2.183

7.  Cardio-facio-cutaneous syndrome with precocious puberty, growth hormone deficiency and hyperprolactinemia.

Authors:  Nurullah Çelik; Peyami Cinaz; Aysun Bideci; Özge Yüce; Hamdi Cihan Emeksiz; Esra Döğer; Orhun Çamurdan
Journal:  J Clin Res Pediatr Endocrinol       Date:  2014

8.  Molecular and clinical studies in 107 Noonan syndrome affected individuals with PTPN11 mutations.

Authors:  Jeevana Praharsha Athota; Meenakshi Bhat; Sheela Nampoothiri; Kalpana Gowrishankar; Sanjeeva Ghanti Narayanachar; Vinuth Puttamallesh; Mohammed Oomer Farooque; Swathi Shetty
Journal:  BMC Med Genet       Date:  2020-03-12       Impact factor: 2.103

Review 9.  New Horizons in the Genetic Etiology of Systemic Lupus Erythematosus and Lupus-Like Disease: Monogenic Lupus and Beyond.

Authors:  Erkan Demirkaya; Sezgin Sahin; Micol Romano; Qing Zhou; Ivona Aksentijevich
Journal:  J Clin Med       Date:  2020-03-05       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.